Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Timetable
Peijia Medical

Peijia Medical Limited focus on interventional procedural medical device market in China, and is a domestic player in each of the transcatheter valve therapeutic medical device market and the neurointerventional procedural medical device market in China.

1. Transcatheter valve therapeutic medical devices: It is one of the only four domestic players in the China market with transcatheter aortic valve replacement (TAVR) products at the clinical trial or more advanced stage, and ranked third in the China transcatheter valve medical device market in terms of the combined number of commercialized products and product candidates in the clinical trial stage, according to Frost & Sullivan. It is in the process of completing the confirmatory clinical trial for TaurusOne, its first-generation TAVR product, and expect to receive the NMPA approval for and launch TaurusOne in the first or second quarter of 2021.

2. Neurointerventional procedural medical devices: It ranked first among domestic players in the China market in terms of the combined number of commercialized products and product candidates in the clinical trial stage, and was the first domestic player to commercialize an embolization coil product in China, according to Frost & Sullivan.

The Group has a comprehensive portfolio of interventional procedural medical device products and product candidates focusing on these two fields. As of 26 April 2020, it had developed six registered products, and had an additional 20 product candidates in various stages of development.

Its two state-of-the-art manufacturing facilities located in Suzhou and Shanghai support both transcatheter valve therapeutic and neurointerventional businesses, and comply with the GMP requirements in the EU and China. It follows rigorous manufacturing and quality control standards to ensure high product quality and safety. It has established an extensive distribution network to sell commercialized products, comprising 65 distributors as at December 31, 2019, including 62 distributors in China and three overseas.

MarketHong Kong (Main Board)
Business NatureHealth Care
Board Lot1,000
Registrar & Transfer OfficeComputershare Hong Kong Investor Services
No. of Offer Shares153m shares
No. of International Offer Shares137m shares
No. of HK Offer Shares15.25m shares
Offer Price$15.36
Nominal ValueUS$ 0.0001 each
Stock Code9996
Joint SponsorsMorgan Stanley Asia, Huatai Financial Holdings (Hong Kong)
Joint Global CoordinatorsMorgan Stanley Asia, Huatai Financial Holdings (Hong Kong), BOCI Asia, UBS AG
Joint Bookrunners and Joint Lead ManagersMorgan Stanley Asia, Huatai Financial Holdings (Hong Kong), BOCI Asia, UBS AG, CMB International Capital, Guotai Junan Securities (Hong Kong)
Application PeriodMay 5 (Tue) - Noon, May 8 (Fri)
Price Determination DateOn or Before 5pm, May 8 (Fri)
Result Announcement DateOn or Before May 14 (Thu)
Dispatch of Shares and Refund ChequesOn or Before May 14 (Thu)
Dealings in Shares commence onMay 15, 2020. (Fri)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
ExecutiveYi ZHANG (Chairman), Ping Ye ZHANG, Hong YE
Non-ExecutiveZhiyun YU, Jifeng GUAN, Fei CHEN, Bing SHANG
Independent Non-ExecutiveStephen Newman OESTERLE, Robert Ralph PARKS, Wayne WU, Wai Ming YIP
Director Yi ZHANG and related parties23.68%
Matrix Partners7.38%
Hillhouse Capital6.84%
(Year ended Dec 31)
Gross Profit12,0130--
Pre-Taxed Profit(531,977)(82,876)--
Attributable Profit for the period(531,977)(82,625)--
Offer Price$15.36
Unaudited pro forma adj NAV / share$4.66
Based on the offer price being at $15.36, the net proceeds raised would be HK$2,200.3m, of which:
* $770.1m (35.0%) for the development and commercialization of Core Product, TaurusOne;
* $660.1m (30.0%) For the development and commercialization of other major product candidates, including TaurusElite, TaurusNXT and Shenyi Stent Retriever;
* $220.0m (10.0%) for ongoing pre-clinical studies and planned clinical trials, preparation for registration filings and potential commercial launches (including sales and marketing) of other product candidates in our pipeline;
* $176.0m (8.0%) for strengthening research and development capabilities;
* $220.0m (10.0%) for expanding product portfolio and intellectual property portfolio;
* the balance of $154.1m (7.0%) as additional working capital.
No related information.
Code Name Nominal Change %Change
01801INNOVENT BIOup59.2002.1003.678%
01877JUNSHI BIO-Bdown58.000-0.100-0.172%
02552HUA MEDICINE-Bdown8.000-0.070-0.867%
02616CSTONE PHARMA-Bdown11.100-0.180-1.596%
03681SINOMAB BIO-Bdown3.800-0.160-4.040%
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
  Quote data is at least 15-min delayed,last updated: 03/07/2020 17:58
IPO Calculator
Subscription --
Result Announcement --      Listing --
Offer Price︰--
Currency :
Listing Price
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.003% and Stock Exchange trading fee of 0.005% (i.e. 1.008% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.